Kyoto University unveils a non-addictive analgesic creation
A potential game-changer in the medical world has been unveiled by researchers at Kyoto University. They have discovered a new painkiller that could significantly reduce the reliance on opioids for chronic pain treatment, potentially contributing to the reduction of opioid use in medical settings.
The new drug, which is non-addictive, works by increasing the secretion of noradrenaline, a neurotransmitter that suppresses pain. This discovery was made by Professor Makoto Tsuda, a neuropharmacology expert currently associated with Kyushu University.
Professor Tsuda, who is also affiliated with the Medical Faculty, Institute of Neuropathology, at the University of Freiburg, stated that if the pain reliever demonstrates efficacy in treating chronic pain that is difficult to treat, it has the potential for widespread use.
A clinical trial conducted at Kyoto University Hospital involving 20 patients who had undergone lung cancer surgery yielded promising results. The focus of the team's research is now shifting towards the treatment of chronic pain with the new painkiller.
The new drug is scheduled for a clinical trial involving hundreds of participants in the United States, starting as early as next year. However, no further information about the specifics of the clinical trial in the United States was provided in the article.
If successful in treating chronic pain, this new painkiller could potentially alleviate severe pain in cancer patients without grave side effects. It could also help reduce the number of deaths from opioid overdose, which reached about 80,000 in the U.S. in 2023.
It is important to note that the new painkiller is not yet available for public use. If put into practical use as early as 2028, as planned by the team working on the new painkiller, it could significantly contribute to the reduction of opioid use in medical settings and provide a much-needed alternative for those suffering from chronic pain.
The team is planning a clinical trial focused on the treatment of chronic pain, with the hope that this new painkiller could offer a viable solution for those who have struggled with the side effects and addictive nature of current pain management options.
Read also:
- High recovery rate for over 90% of patients, asserts the head physician of Almaty's 32nd polyclinic, regarding mobile treatment groups.
- Bee colonies in Zirndorf city have been affected by American foulbrood - a designated restriction zone has been established - no immediate threat to local residents.
- Federal Health Care Blueprint for 2026 Revealed by OPM Outlining Key Strategies and Objectives
- Unveiling the Undiscussed Issues of Earbuds: Revealing the Silent Reality
